Frazier Life Sciences led a $200m Series A round in AirNexis Therapeutics.

Frazier Life Sciences, a healthcare investment firm, led a $200m Series A round in AirNexis Therapeutics, a clinical stage biotech company developing therapeutics for pulmonary diseases, with participation from OrbiMed, SR One, Life Sciences at Goldman Sachs Alternatives, Longitude Capital and Enavate Sciences. “Company creation is a key strategy for Frazier, and we are excited to launch AirNexis as a new company focused on the global development of this compelling clinical stage asset. We look forward to collaborating with Haisco, our co-investors and the management team to work towards building a leading respiratory company and advancing meaningful new therapies for patients," Anna Chen, Frazier Life Sciences Partner.